The year-old union of bioMerieux-Pierre Fabre appears to be on the verge of disintegrating, amid lack of a coherent strategy, disagreements between the two founders who spearheaded the deal, and departure of key top executives. The company won't comment except to say that it is considering various alternatives including a break-up. Unraveling should not be difficult, since the two companies haven't integrated much. And the separation would leave bioMerieux, now the world's eighth largest diagnostics company, and Pierre Fabre, one of France's largest independent pharmaceutical companies, free to seek more appropriate solutions to the challenges they face.
When French newspapers reported in late January that
bioMerieux-Pierre Fabre SA was ending its year-old merger,
few knowledgeable people were surprised. The union in January 2001
created France's largest independent pharmaceutical company
[See Deal]. (See "BioMerieux and Pierre Fabre's
Surprise," IN VIVO, October 2000 [A#2000800180.) But the
rationale behind it—to better compete in consolidating
industries—remained unconvincing.
As the world's eighth largest diagnostics company, bioMerieux SA's expertise has been in infectious diseases. Pierre Fabre SA, one of...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.